среда, 22 июня 2016 г.

3 Ways This $30 Billion Market Is Bristol's for the Taking

3 Ways This $30 Billion Market Is Bristol's for the Taking


Just three years ago, Bristol-Myers Squibb took a huge gamble selling its diabetes unit in a $4 billion deal to refocus its efforts on immuno-oncology , a novel approach aimed at using drugs to boost the immune response to cancer. For a sluggish "Big Pharma" attempting a turnaround, this was a big bet in new and relatively unknown territory.



from Biotech News